FIELD: medicine.
SUBSTANCE: what is described is a method for providing an immunosuppressive once-a-day treatment of a patient, preferentially a patient with a renal or hepatic graft by administering an extended-release oral tablet. The tablet contains 0.1 to 15 mg of tacrolimus, hydroxypropyl metylcellulose, lactose monohydrate, polyethylene glycol 6000, poloxamer 188, magnesium stearate, tartaric acid, butylated hydroxytoluene and dimethicone 350.
EFFECT: tacrolimus tablet releases an active substance with a zero-order linear release profile from the moment of time 8 hours prior to the moment of time 15 hours; it also provides the improved pharmacokinetic parameters, including lower maximum concentrations, despite higher bioavailability, longer periods of maximum concentration time and higher minimum concentrations as compared to conventional dosage forms of tacrolimus.
18 cl, 10 dwg, 30 tbl, 24 ex
